Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Year: 2005
Type: article
Abstract: Dexamethasone alone increases life expectancy in patients with relapsed multiple myeloma (MM); however, no large randomized study has compared dexamethasone and dexamethasone-based regimens with standard melphalan-prednisone in newly diagnosed MM patients ineligible for high-dose therapy. In the Intergroupe Francophone du Myélome (IFM) 95-01 trial, 488 patients aged 65 to 75 years were randomized between 4 regimens of treatment: melphalan-prednisone, dexamethasone alone, melphalan-dexamethasone, and dexamethasone-interferon alpha. Response rates at 6 months (except for complete response) were significantly higher among patients receiving melphalan-dexamethasone, and progression-free survival was significantly better among patients receiving melphalan (P < .001, for both comparisons), but there was no difference in overall survival between the 4 treatment groups. Moreover, the morbidity associated with dexamethasone-based regimens was significantly higher than with melphalan-prednisone, especially for severe pyogenic infections in the melphalan-dexamethasone arm and hemorrhage, severe diabetes, and gastrointestinal and psychiatric complications in the dexamethasone arms. Overall, these results indicated that dexamethasone should not be routinely recommended as first-line treatment in elderly patients with MM. In the context of the IFM 95-01 trial, the standard melphalan-prednisone remained the best treatment choice when efficacy and patient comfort were both considered. These results might be useful in the context of future combinations with innovative drugs.
Source: Blood
Authors: T. Facon, Jean-Yves Mary, Brigitte Pégourie, Michel Attal, Marc Renaud, Alain Sadoun, Laurent Voillat, Véronique Dorvaux, Cyrille Hulin, Gérard Lepeu, Jean-Luc Harousseau, Jean-Paul Eschard, Augustin Ferrant, Michel Blanc, Frédéric Maloisel, Hubert Orfeuvre, Jean-François Rossi, Isabelle Azaïs, Mathieu Monconduit, Philippe Collet, Bruno Anglaret, Ibrahim Yakoub-Agha, Marc Wetterwald, Houchingue Eghbali, Marie-Christine Vekemans, Hervé Maisonneuve, Jacques Troncy, Bernard Grosbois, Chantal Doyen, Antoine Thyss, Jérome Jaubert, Philippe Casassus, Béatrice Thielemans, Régis Bataille
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2146000276
